MetfOrmin BenefIts Lower Extremities With Intermittent Claudication

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-01

Study Completion Date

2031-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Peripheral arterial disease (PAD) affects over 20% of aged adults and is very common among Veterans due significant tobacco use. PAD is due to the progressive blockage of peripheral arteries, predominantly to the legs, and results in intermittent claudication (IC) or recurrent muscle pain with activity secondary to insufficient blood supply. Those with PAD and IC experience a progressive decline in walking and poor quality of life. There is no effective medical treatment for PAD and IC. Metformin is a safe and effective treatment for Type 2 diabetes but it can also reduce inflammation, oxidative stress, and improve energy requirements as well as improve blood flow to the legs. Therefore, the investigators will test the ability of Metformin to improve overall functional status, reduce PAD progression, and reduce systemic inflammation in Veterans suffering from PAD and IC in a randomized, placebo controlled trial: Metformin BenefIts Lower Extremities with Intermittent Claudication (MOBILE IC) Trial. The success of this trial may identify a safe and effective treatment for PAD and IC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanisms That Produce the Leg Dysfunction of Claudication & Treatment Strategies

NCT01970332

Peripheral Arterial Disease

COMPLETED NA

Activity To Improve Outcomes in Peripheral Arterial Disease

NCT02189018

Peripheral Arterial Occlusive Disease

COMPLETED NA

Claudication, Systematic Evaluation of Limp on Treadmill

NCT02754804

Peripheral Artery Disease

COMPLETED

FIRE-PAD: Functional Improvement Through Revascularization of the Extremities for Peripheral Arterial Disease

NCT00274157

Peripheral Vascular Disease

TERMINATED

Lower Extremity Peripheral Arterial Disease and Exercise Ischemia

NCT02041169

Peripheral Arterial Diseases Intermittent Claudication

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a quadruple blinded randomized controlled trial. Therefore, the allocation of participants to either placebo or metformin is unknown by the participant, research personnel, investigator, or blinded statistician. A total of 200 participants will be randomized over the course of 3 years. Study drug is administered to participants after all inclusion and no exclusion criteria is confirmed, informed consent is completed, and they are randomized. Study drug is continued throughout for 6 months following randomization. Participants are prospectively observed and monitored for 12 months after randomization. The patients' involvement (study visits/study phone calls) will last 12 months. Then, for 5 years, the study team will do a medical chart review as outlined in the ICF and protocol. All main study endpoints are within the 12-month time point. Secondary endpoints including MACE and MALE - major adverse cardiac and major adverse limb events - are time to event end points which can continue beyond the 12-month study time frame and will inform not only the effect of metformin on IC but also the natural history of IC among patients enrolled in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intermittent Claudication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Two arm randomization to 1000mg metformin ER or placebo daily with 1:1 parallel randomization, Randomization stratification will be based on baseline Maximum Walking Distance on the 6 Minute Walk Test and smoking status

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

This is a triple-blinded randomized controlled trial. Therefore, the allocation of participants to either placebo or metformin is unknown by the participant, research personnel, and investigator. The study statistician will not be blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metformin ER 1000mg

daily by mouth

Group Type EXPERIMENTAL

Metformin ER

Intervention Type DRUG

Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties

Matching placebo

daily by mouth

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Matched to active study drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin ER

Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties

Intervention Type DRUG

placebo

Matched to active study drug

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glucophage

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and Female Veteran \>35 \& \<89
* Symptoms of Intermittent claudication
* Medically stable, optimal medical therapy (for \>3 months prior to randomization which includes - statin and anti-platelet therapy, blood pressure control, smoking cessation and physical activity counseling)

* PAD as defined by ABI \<0.9 or \>0.9 with evidence of PAD as documented by pulse volume recordings (within 6 months prior to expected randomization date)
* Maximum Walking Distance (MWD) on the 6-minute walk test (6MWT) of greater than or equal to 50 meters with onset of pain before or at 400 meters without the use of a walker (cane is acceptable; within 6 months of expected randomization date)

Exclusion Criteria

* Diabetes (Type I or II) or Hemoglobin A1c\>6.5 (within 6 months of expected randomization)
* Currently Taking metformin or have previously taken metformin (within 6 months of enrollment)
* Medical condition that limit their ability to ambulate other than PAD (i.e., Angina, CHF, pulmonary disease requiring oxygen, malignancy requiring treatment, etc.)
* Prior above or below knee amputation
* Critical limb threatening ischemia (i.e., non-healing wounds or rest pain)
* Planned hospital admission, major operation, or lower extremity revascularization to be completed (within 12 months after expected randomization date)
* Prior major operation or lower extremity revascularization (within the 3 months before expected randomization)
* Unable to complete quality of life testing due to Non-English Speaking and/or Dementia
* Kidney disease - dialysis or eGFR\<45 (within 6 months of expected randomization date)\*
* Planned iodinated contrasted study (within 6 months of expected randomization date)
* Evidence current or history of hepatic failure
* Women who are pregnant or breast feeding
* Unable to swallow uncrushed pills
* Investigator expects inclusion could cause harm to subject

Minimum Eligible Age

35 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No